

Male Osteoporosis

Konstantinos Gkastaris, MD MRCP (London) PhD

Department of Endocrinology, Diabetes and Metabolism, St Luke's Hospital, Thessaloniki, Greece

ABSTRACT

Osteoporosis is a chronic condition characterized by impaired bone remodelling that results in reduced bone mineral density, excessive bone loss and increased fracture risk. Osteoporosis in men is a fairly common condition, affecting 2-8% of men worldwide and more than 30% by the age of 85. Despite these compelling figures, the condition is under-estimated, under-diagnosed and under-treated. As a result and since the condition is almost always a “silent disease”, the first presentation is often a fragility fracture. Although the mechanisms and conditions that cause osteoporosis in men are similar to those in women, male osteoporosis has some unique features. Risk factors in men are very heterogeneous and hypogonadism represents a common underlying cause. Other common aetiological factors are poor vitamin D and calcium levels, chronic underlying haematological, gastroenterological and rheumatological conditions and use of offending drugs or substances. The evidence for diagnosis, screening and treatment of male osteoporosis is quite poor and most of the current knowledge is extrapolated from the female counterpart. Identification and prompt therapy of underlying conditions leading to osteoporosis is essential before additional anti-resorptive or anabolic treatment is considered. This review discusses the current evidence on pathophysiology, aetiology, diagnosis, screening and treatment of osteoporosis in men.

KEYWORDS: Male osteoporosis, osteoporosis, fracture risk, hypogonadism, pharmacological treatment

CORRESPONDING
AUTHOR,
GUARANTOR

Konstantinos Gkastaris, MD MRCP (London) PhD,
Department of Endocrinology, Diabetes and Metabolism,
St Luke's Hospital, Thessaloniki, Greece

Introduction

Osteoporosis is a common disease characterized by low bone mass with microarchitectural disruption and skeletal fragility, resulting in an increased risk of fracture. It is a leading cause of morbidity and mortality in older people as well as a significant financial burden to health systems worldwide.

Although the mechanisms and conditions that cause osteoporosis in men are similar to those in women, male osteoporosis has some unique features. Furthermore, epidemiological data and clinical experience suggest that osteoporosis in men is overlooked and often diagnosed late when an osteoporotic fracture has already occurred. Epidemiological surveys show that causes or contributing factors for osteoporosis can be identified in a significant percentage of men who have sustained an osteoporotic fracture, a finding illustrating the importance and value of early diagnosis and treatment in order to prevent the fracture.

The epidemiology, aetiology, clinical evaluation and treatment of osteoporosis in men will be reviewed in this chapter.

Epidemiology

In the developed world, 2% to 8% of males are affected by osteoporosis (1, 2). By the age of 85 years, over 30 percent of men will have a femoral neck T-score at or below -2.5 (3).

Although the fracture risk for men is lower compared to women, it remains significant: A 60-year-old man has a 25% risk of fracture (compared to 44% for a woman of the same age) (4). Furthermore, 1 in 5 men over the age of 50 will sustain an osteoporotic fracture (5).

Pathophysiology

The underlying mechanism in all cases of osteoporosis is an imbalance between bone formation and bone resorption. Low bone mass density can occur either when pubertal bone accretion is reduced resulting in suboptimal peak bone mass or when the rate of bone resorption is accelerated after peak bone mass is achieved: that takes place when osteoclasts are degrading the bone matrix faster than the osteoblasts are rebuilding the bone (6).

Pubertal bone accretion – achievement of peak bone mass

Peak bone mass is defined as the amount of bony tissue present at the end of the skeletal maturation and represents the maximum amount of bone an individual can attain during his life. The exact age of peak bone mass is unclear and can be affected by a number of factors (genetic, ethnic, hormonal, environmental). However, it probably occurs around the mid-thirties in most people.

In men, there is a dramatic increase of bone mass during puberty and the peak bone mass seems to be skeletal site-specific: it occurs around the age of 20 in the spine but later on in life in femur and radius (7).

One major factor is the *timing of onset of puberty*. The evidence suggests that there is a critical time window during which adequate concentrations of sex steroids is essential in order to achieve the optimal bone mass. Adult men with a history of constitutionally delayed puberty have decreased radial and spinal bone mineral density (8) as well as femoral bone density (9). Furthermore, this bone deficit does not seem to be corrected with age even when the steroids' levels are restored (8, 9).

Another major determinant of peak bone mass is intact production of *gonadal steroids*. The findings suggest that men with idiopathic hypogonadotrophic hypogonadism have lower cortical and trabecular bone mass (10) which is improved after correction of the hormonal deficit (11). Interestingly, *both androgens and oestrogens* have profound effect on peak bone mass in men.

Age-related bone loss

The imbalance between bone resorption and bone formation is responsible for bone loss after the peak bone mass is achieved. In men, trabecular bone loss appears to start prior to cortical bone loss and typically soon after the peak bone mass is achieved (12).

Aetiology

Male osteoporosis has historically been classified into two main categories, primary and secondary. Furthermore, primary osteoporosis can be further

TABLE 1. Causes of osteoporosis in men

Endocrine conditions	Haematological conditions	Other conditions	Drugs and substances
Hypogonadism - delayed puberty	Multiple myeloma	Rheumatoid arthritis	Alcohol Tobacco
Diabetes mellitus (type 1, 2)	Mastocytosis	Renal and hepatic disease	Overreplacement with levothyroxine
Estrogen deficiency	Chronic anemia	Immobilisation	Glucocorticoids
Hypercortisolism (Cushing's)	Gastrointestinal conditions	Osteogenesis imperfecta	Heparin
Hyperthyroidism	Coeliac disease	Homocystinuria	Anticonvulsants
Hyperparathyroidism	Inflammatory bowel disease	Ehlers-Danlos syndrome	Chemotherapy Immunotherapy
Vitamin D deficiency	Malabsorption	Marfan syndrome	Protein pump inhibitors
Growth hormone deficiency	Cirrhosis	Eating disorders (anorexia nervosa)	Cyclosporine Anti-retrovirals Lithium

divided into i) involutional (or senile) osteoporosis, which occurs in men older than 70 years old with no other risk factor present, and ii) idiopathic osteoporosis, which occurs in patients younger than 70 years old without risk factors (13).

It should be noted however that, even though the underlying conditions that cause osteoporosis in men are similar to those in women, diagnostic search is often less vigorous and active in men, especially when no apparent risk factors are presents. Epidemiological surveys suggest that secondary causes can be identified in 40-60% of men who have severe osteoporosis or have sustained osteoporotic fractures (14, 15).

The medical conditions and risk factors for osteoporosis are summarised in Table 1. Some of these conditions and risk factors have been shown to be most predictive of osteoporotic fractures in men (16, 17, 18):

- Hypogonadism
- Low calcium and vitamin D levels
- Alcohol and tobacco use
- Low bone mineral density (BMD)
- Advancing age
- Prior history of fragility fracture

- Chronic glucocorticoid use and
- Parental history of hip fracture

Hypogonadism, both primary and secondary, is a common of osteoporosis in men. As previously discussed in this chapter, sex steroids play a key role in attainment of peak bone mass. Testosterone levels are also pivotal for maintenance of bone mass: the balance between bone formation and disruption is affected when testosterone levels fall < 200ng/dL as it seems that bone turnover increases at this point probably due to a parallel fall of serum oestrogen <15 pg/mL (19). It is well documented that low levels of oestradiol can increase the risk of fractures in men (20, 21) and this is probably be due to a deficit of testosterone transformation into oestradiol secondary to an aromatase enzyme dysfunction. Furthermore, hypogonadism lead to muscular atrophy, muscle mass loss and sarcopenia, factors further contributing to the risk of fractures.

Low serum vitamin D levels and poor calcium intake. The negative impact of low vitamin D levels on skeletal health is well-documented (22, 23). It is estimated that around 15% of male osteoporosis is caused by vitamin D deficiency (24). Suboptimal calcium intake (less than 1.200mg) is fairly common in el-

TABLE 2. Diagnostic criteria for osteoporosis and osteopenia in men ≥ 50 years based upon DXA measurements (33, 34)

Category	Bone mass
Normal	BMD value within 1.0 SD of the young adult female reference mean (T-score ≥ -1.0)
Osteopenia	BMD more than 1.0 but less than 2.5 SD below the young adult female reference mean ($-2.5 < \text{T-score} < -1.0$)
Osteoporosis	BMD value 2.5 or more SD below the young adult female reference mean (T-score ≤ -2.5)
Severe osteoporosis	T-score ≤ -2.5 and one or more fragility fractures

TABLE 3. Laboratory work-up

In all cases	In most cases
Full blood count	Testosterone
Calcium (corrected for albumin too)	Parathyroid hormone
Phosphorus	Serum/urine protein electrophoresis
Erythrocyte sedimentation rate	Thoracic-lumbar spine X-ray (Face/Profile)
Creatinine	In selected cases
Alkaline phosphatase	24hour urinary free cortisol
25 (OH) Vitamin D	Serum tryptase
TSH	Anti-Tissue Transglutaminase antibodies
24hour urinary calcium	Bone turnover markers (P1NP or CTx)

derly men. There is some evidence from trials supporting the role of calcium and vitamin D correction in men (25, 26) in terms of bone mass. However, the evidence is less clear for risk of fractures (27).

Cigarette smoking and excessive *alcohol consumption* are associated with accelerated bone loss and fracture risk (28, 29, 30) although the underlying mechanism is not entirely clear.

Glucocorticoid excess, either endogenous or iatrogenic has a negative impact on male skeletal health. This is primarily due to the direct impact on the bone, but also due to the secondary hypogonadism and sarcopenia the steroids' excess can induce.

Clinical manifestations

Osteoporosis is a silent disease. It doesn't give any symptoms until a fracture occurs. Even then, some of these fractures are incidental findings on imaging done for other purposes as they can be asymptomatic. However, it should be noted that these men often have symptoms of the underlying condition

(endocrine, gastrointestinal, connective tissue) that predisposes to osteoporosis therefore there should be a high degree of clinical suspicion.

Typical fragility fractures occur in the vertebral column, the ribs, the hip and the wrist. Men sustain fewer fragility fractures than women but their mortality is higher than women following a fragility fracture (31).

Diagnosis

In all men, irrespective of age, a clinical diagnosis of osteoporosis can be made in the presence of a fragility fracture. In all other cases, bone mineral density (BMD) assessment by dual-energy x-ray absorptiometry (DXA) should be performed. DXA is considered the gold standard test to diagnose osteoporosis in men ≥ 50 years even though it is not as well standardised as in postmenopausal women. There has been some controversy regarding the reference database for the calculation of T-scores in men. This is because it is documented that at any

skeletal site T-score men have a lower absolute risk for fracture than women (32). Nonetheless, both the World Health Organisation and the International Society for Clinical Densitometry (ISCD) recommend the use of a female reference database for men over the age of 50, rather than using healthy young males as reference (33, 34). The diagnostic cut-offs are summarised in Table 2.

For younger men, aged <50 years, the diagnosis should not be made on BMD measurements alone (34). In these individuals, a low Z-score ≤ -2.0 alone is not necessarily suggestive of osteoporosis, unless there is a history of a fragility fracture or a secondary cause for osteoporosis is present.

Value of screening – who should be tested for osteoporosis

Routine male population screening for osteoporosis based solely on age has been a controversial issue. However, an increasing number of groups, institutions and societies such as the National Osteoporosis Foundation (NOF), International Society for Clinical Densitometry (ISCD), and the Endocrine Society recommend BMD testing for all men older than 65 or 70 as it is probably a cost-effective approach. This approach is reflected on the guidelines for diagnosis and treatment of osteoporosis in Greece (35), which recommend routine DXA measurement in all men above the age of 65. In younger men, under the age of 65, BMD testing should be performed when i) there is clinical evidence of possible low bone mass (fragility fracture, evidence of osteopenia in other forms of radiography) and/or ii) there are underlying conditions that predispose to osteoporosis (as summarised in Table 1).

Fracture Risk Assessment Tool (FRAX)

The FRAX score represents a diagnostic tool used to evaluate the 10-year probability of fracture. It integrates clinical risk factors and BMD at the femoral neck to calculate the 10-year probability of hip fracture and the 10-year probability of a major osteoporotic fracture and can be used in men as an aid to the clinician, although its intervention thresholds increase the proportion of older men who are candidates for therapy compared to the WHO criteria (36).

Diagnostic approach to the man with osteoporosis for secondary causes

Detailed history should be obtained and thorough clinical examination should be performed in any man diagnosed with osteoporosis as they can potentially point towards a possible underlying diagnosis. The laboratory work-up is summarised in Table 3. It should be noted, that, if a rarer underlying condition is suspected, the relevant investigations should be performed.

Treatment

The treatment of osteoporosis in men consists of a) non-pharmacological measures, b) calcium and vitamin D correction, c) treatment of potential underlying causes and d) pharmacological measures.

Non-pharmacological measures

Lifestyle measures and modifications should be encouraged for men with osteoporosis. Weight bearing exercise has been shown to be beneficial by a) increasing muscular strength, b) potentially increasing bone mass, c) improving co-ordination thus preventing falls (37, 38, 39).

Calcium and vitamin D

The estimated daily calcium requirements are 1000mg for men aged 19-70 and 1200mg for men over the age of 70. Suboptimal serum calcium concentrations is a fairly common problem in elderly men, predominantly due to poor intestinal absorption (mainly due to polypharmacy) and reduced glomerular filtration therefore oral supplementation of 500-1000 mg/day of calcium carbonate is typically suggested.

Poor serum vitamin D concentrations is another common problem, especially amongst older men residing in institutions. Various dosing regimens have been proven to treat vitamin D deficiency in men. Most groups and societies suggest a daily vitamin D supplementation of 600-800 I.U.

Treatment of underlying conditions

Secondary causes can be identified in 40-60% of men who have severe osteoporosis or have sustained osteoporotic fractures (14, 15). This under-

lines the importance of prompt and appropriate management of the underlying cause for osteoporosis (see Table 1 for the various causes). Offending medications should be discontinued if that's possible or have their dose reduced. There are some special considerations for some of these underlying conditions:

Hypogonadism is a common cause for osteoporosis in men. Proper assessment of the hypogonadism, calculation of the bioavailable/active testosterone and the decision to treat with testosterone balancing the cardiovascular risk is an important aspect of treatment of osteoporosis in hypogonadal men. There are quite convincing data that correction of the hormonal deficit in younger men with clear aetiology for the hypogonadism (e.g. pituitary tumour, Klinefelter syndrome) increases bone mass (40, 41, 42, 43). The evidence is less clear for older men as only a few small trials (44, 45, 46) and the "Testosterone Trials" (47) have examined the efficacy of testosterone on bone mass. The improvement on bone mass following administration of testosterone in older men is similar to the one observed in the placebo groups. It is probably recommended that the decision to treat with testosterone in older men should be taken on an individualised basis taking into account the cardiovascular risk as well.

An area of debate is whether testosterone replacement therapy is adequate in a man with osteoporosis due to hypogonadism or whether additional anti-osteoporotic treatment is necessary. In the absence of any strong clinical data, the recommendation of the Endocrine Society is to add an anti-osteoporotic pharmacological agent to the hypogonadal men with high fracture risk alone (48). Risk factors include a previous fragility fracture, severe osteoporosis (defined as T-score ≤ -3.0), treatment with high dose glucocorticoids and persistent osteoporosis despite successful correction of the hypogonadism for at least 2 years.

Osteoporosis due to gastrointestinal diseases (commonly celiac disease or inflammatory bowel disease) is characterised by the low, and often very low, calcium and vitamin D concentrations and secondary hyperparathyroidism therefore these

patients often require higher doses of calcium and vitamin D.

Glucocorticoid-induced osteoporosis is a relatively common cause of osteoporosis in men and is observed even with relatively low doses of exogenous steroids (equivalent to prednisolone 5-7.5 mg). The bone loss is more aggressive in the first months of treatment with steroids therefore it should be treated aggressively, particularly in those already at high risk for fracture.

Pharmacological measures

With regards to the pharmacological approach to osteoporosis in men, there are two questions: which patient to treat and what the treatment options are.

Whom to treat?

For hypogonadal men, the indications for additional to testosterone treatment have been discussed earlier in this chapter (see "Treatment of underlying conditions" section).

For eugonadal men, the indication for pharmacological treatment are: a) history of fragility fracture, b) established osteoporosis, c) osteopenia (48, 49).

Treatment options


Bisphosphonates is the first line treatment for most men with osteoporosis. Most groups suggest oral alendronate or risendronate as initial therapy (48, 50, 51) since randomized trials (52, 53, 54, 55, 56) have proven the efficacy and safety of these medications (down to eGFR 30-35 ml/min). When oral bisphosphonate is contraindicated or not tolerated, zoledronate can be used (57, 58).

Denosumab is a potent anti-resorptive agent and has a role for treatment of osteoporosis in men especially when a) bisphosphonates are not tolerated or not effective and b) the patient's renal function is poor (eGFR $< 30-35$ ml/min). It should be noted that denosumab has been shown to improve bone mass in men (59), but there are no data about fracture risk reduction.

Teriparatide has been shown to be effective in improving the spinal and femoral BMD in men (60).

Similar results have been shown for *abaloparatide* (61), but none of these trials assessed fractures. In most guidelines, these agents are reserved for men with severe osteoporosis or men with osteoporosis and a new fracture or men who did not respond to previous treatment. It is crucial that treatment with

these agents is always followed by an antiresorptive agent.

Romosozumab, an agent with mixed anabolic and antiresorptive action, has shown an improvement in spinal and total hip BMD in men (62). 

REFERENCES

1. Wade, S.W., Strader, C., Fitzpatrick, L.A. et al. Estimating prevalence of osteoporosis: examples from industrialized countries. *Arch Osteoporos* 9, 182 (2014).
2. Osteoporosis or Low Bone Mass in Older Adults: United States, 2017–2018; NCHS Data Brief, March 2021. Available at: www.cdc.gov/nchs/products/databriefs/db405.htm (Accessed on October 18, 2022).
3. Trajanoska K, Schoufour JD, de Jonge EAL, Kieboom BCT, Mulder M, Stricker BH, Voortman T, Uitterlinden AG, Oei EHG, Ikram MA, Zillikens MC, Rivadeneira F, Oei L. Fracture incidence and secular trends between 1989 and 2013 in a population based cohort: The Rotterdam Study. *Bone*. 2018 Sep;114:116-124.
4. Ji MX, Yu Q. Primary osteoporosis in postmenopausal women. *Chronic Dis Transl Med*. 2015 Mar 21;1(1):9-13.
5. Wright NC, Looker AC, Saag KG, Curtis JR, Delzell ES, Randall S, et al. The recent prevalence of osteoporosis and low bone mass in the United States based on bone mineral density at the femoral neck or lumbar spine. *J Bone Miner Res*. 2014
6. Robling AG, Bonewald LF. The Osteocyte: New Insights. *Annu Rev Physiol*. 2020 Feb 10;82:485-506.
7. Bonjour JP, Theintz G, Buchs B, Slosman D, Rizzoli R. Critical years and stages of puberty for spinal and femoral bone mass accumulation during adolescence. *J Clin Endocrinol Metab*. 1991 Sep;73(3):555-63.
8. Finkelstein JS, Neer RM, Biller BM, Crawford JD, Klibanski A. Osteopenia in men with a history of delayed puberty. *N Engl J Med*. 1992 Feb 27;326(9):600-4.
9. Finkelstein JS, Klibanski A, Neer RM. A longitudinal evaluation of bone mineral density in adult men with histories of delayed puberty. *J Clin Endocrinol Metab*. 1996 Mar;81(3):1152-5.
10. Finkelstein JS, Klibanski A, Neer RM, Greenspan SL, Rosenthal DI, Crowley WF Jr. Osteoporosis in men with idiopathic hypogonadotropic hypogonadism. *Ann Intern Med*. 1987 Mar;106(3):354-61.
11. Guo CY, Jones TH, Eastell R. Treatment of isolated hypogonadotropic hypogonadism effect on bone mineral density and bone turnover. *J Clin Endocrinol Metab*. 1997 Feb;82(2):658-65.
12. Riggs BL, Melton LJ, Robb RA, Camp JJ, Atkinson EJ, McDaniel L, Amin S, Rouleau PA, Khosla S. A population-based assessment of rates of bone loss at multiple skeletal sites: evidence for substantial trabecular bone loss in young adult women and men. *J Bone Miner Res*. 2008 Feb;23(2):205-14.
13. Gennari L, Bilezikian JP. New and developing pharmacotherapy for osteoporosis in men. *Expert Opin Pharmacother*. 2018 Feb;19(3):253-264.
14. Orwoll ES, Klein RF. Osteoporosis in men. *Endocr Rev*. 1995 Feb;16(1):87-116.
15. Riggs BL, Melton LJ, Robb RA, Camp JJ, Atkinson EJ, McDaniel L, Amin S, Rouleau PA, Khosla S. A population-based assessment of rates of bone loss at multiple skeletal sites: evidence for substantial trabecular bone loss in young adult women and men. *J Bone Miner Res*. 2008 Feb;23(2):205-14.
16. Scane AC, Francis RM, Sutcliffe AM, Francis MJ, Rawlings DJ, Chapple CL. Case-control study of the pathogenesis and sequelae of symptomatic vertebral fractures in men. *Osteoporos Int*. 1999;9(1):91-7.
17. Kanis JA, Oden A, Johansson H, Borgström F, Ström O, McCloskey E. FRAX and its applications to clinical practice.

- cal practice. *Bone*. 2009 May;44(5):734-43.
18. Lewis CE, Ewing SK, Taylor BC, Shikany JM, Fink HA, Ensrud KE, Barrett-Connor E, Cummings SR, Orwoll E; Osteoporotic Fractures in Men (MrOS) Study Research Group. Predictors of non-spine fracture in elderly men: the MrOS study. *J Bone Miner Res*. 2007 Feb;22(2):211-9.
 19. Finkelstein JS, Lee H, Leder BZ, Burnett-Bowie SA, Goldstein DW, Hahn CW, Hirsch SC, Linker A, Perros N, Servais AB, Taylor AP, Webb ML, Youngner JM, Yu EW. Gonadal steroid-dependent effects on bone turnover and bone mineral density in men. *J Clin Invest*. 2016 Mar 1;126(3):1114-25.
 20. Szulc P, Munoz F, Claustrat B, Garnero P, Marchand F, Duboeuf F, Delmas PD. Bioavailable estradiol may be an important determinant of osteoporosis in men: the MINOS study. *J Clin Endocrinol Metab*. 2001 Jan;86(1):192-9.
 21. Barrett-Connor E, Mueller JE, von Mühlen DG, Laughlin GA, Schneider DL, Sartoris DJ. Low levels of estradiol are associated with vertebral fractures in older men, but not women: the Rancho Bernardo Study. *J Clin Endocrinol Metab*. 2000 Jan;85(1):219-23.
 22. Diamond T, Smerdely P, Kormas N, Sekel R, Vu T, Day P. Hip fracture in elderly men: the importance of subclinical vitamin D deficiency and hypogonadism. *Med J Aust*. 1998 Aug 3;169(3):138-41.
 23. Wicherts IS, van Schoor NM, Boeke AJ, Visser M, Deeg DJ, Smit J, Knol DL, Lips P. Vitamin D status predicts physical performance and its decline in older persons. *J Clin Endocrinol Metab*. 2007 Jun;92(6):2058-65.
 24. Looker AC, Mussolino ME. Serum 25-hydroxyvitamin D and hip fracture risk in older U.S. white adults. *J Bone Miner Res*. 2008 Jan;23(1):143-50.
 25. Daly RM, Brown M, Bass S, Kukuljan S, Nowson C. Calcium- and vitamin D3-fortified milk reduces bone loss at clinically relevant skeletal sites in older men: a 2-year randomized controlled trial. *J Bone Miner Res*. 2006 Mar;21(3):397-405.
 26. Meier C, Woitge HW, Witte K, Lemmer B, Seibel MJ. Supplementation with oral vitamin D3 and calcium during winter prevents seasonal bone loss: a randomized controlled open-label prospective trial. *J Bone Miner Res*. 2004 Aug;19(8):1221-30.
 27. Cranney A, Weiler HA, O'Donnell S, Puil L. Summary of evidence-based review on vitamin D efficacy and safety in relation to bone health. *Am J Clin Nutr*. 2008 Aug;88(2):513S-519S.
 28. Moinuddin MM, Jameson KA, Syddall HE, Sayer AA, Martin HJ, Robinson S, Cooper C, Dennison EM. Cigarette smoking, birthweight and osteoporosis in adulthood: results from the hertfordshire cohort study. *Open Rheumatol J*. 2008;2:33-7.
 29. Jutberger H, Lorentzon M, Barrett-Connor E, Johansson H, Kanis JA, Ljunggren O, Karlsson MK, Rosengren BE, Redlund-Johnell I, Orwoll E, Ohlsson C, Mellström D. Smoking predicts incident fractures in elderly men: Mr OS Sweden. *J Bone Miner Res*. 2010 May;25(5):1010-6.
 30. Drake MT, Murad MH, Mauck KF, Lane MA, Undavalli C, Elraiyah T, Stuart LM, Prasad C, Shahrour A, Mullan RJ, Hazem A, Erwin PJ, Montori VM. Clinical review. Risk factors for low bone mass-related fractures in men: a systematic review and meta-analysis. *J Clin Endocrinol Metab*. 2012 Jun;97(6):1861-70.
 31. Haentjens P, Magaziner J, Colón-Emeric CS, Vanderschueren D, Milisen K, Velkeniers B, Boonen S. Meta-analysis: excess mortality after hip fracture among older women and men. *Ann Intern Med*. 2010 Mar 16;152(6):380-90.
 32. Cummings SR, Cawthon PM, Ensrud KE, Cauley JA, Fink HA, Orwoll ES; Osteoporotic Fractures in Men (MrOS) Research Groups; Study of Osteoporotic Fractures Research Groups. BMD and risk of hip and nonvertebral fractures in older men: a prospective study and comparison with older women. *J Bone Miner Res*. 2006 Oct;21(10):1550-6.
 33. Kanis JA, McCloskey EV, Johansson H, Oden A, Melton LJ 3rd, Khaltayev N. A reference standard for the description of osteoporosis. *Bone*. 2008 Mar;42(3):467-75.
 34. Adult Official Positions of the ISCD as updated in 2019 (available on iscd.org)
 35. Guidelines for the diagnosis and management of osteoporosis, Hellenic Society for the Study of Bone Metabolism, updated 2018 (available at eemmo.gr)

36. World Health Organization. WHO Fracture Risk Assessment Tool. Available from: <http://www.shef.ac.uk/FRAX>.
37. Kukuljan S, Nowson CA, Sanders KM, Nicholson GC, Seibel MJ, Salmon J, Daly RM. Independent and combined effects of calcium-vitamin D3 and exercise on bone structure and strength in older men: an 18-month factorial design randomized controlled trial. *J Clin Endocrinol Metab*. 2011 Apr;96(4):955-63.
38. Fortinsky RH, Iannuzzi-Sucich M, Baker DI, Gottschalk M, King MB, Brown CJ, Tinetti ME. Fall-risk assessment and management in clinical practice: views from healthcare providers. *J Am Geriatr Soc*. 2004 Sep;52(9):1522-6.
39. Body JJ, Bergmann P, Boonen S, Boutsen Y, Bruyere O, Devogelaer JP, Goemaere S, Hollevoet N, Kaufman JM, Milisen K, Rozenberg S, Reginster JY. Non-pharmacological management of osteoporosis: a consensus of the Belgian Bone Club. *Osteoporos Int*. 2011 Nov;22(11):2769-88.
40. Katznelson L, Finkelstein JS, Schoenfeld DA, Rosenthal DI, Anderson EJ, Klibanski A. Increase in bone density and lean body mass during testosterone administration in men with acquired hypogonadism. *J Clin Endocrinol Metab*. 1996 Dec;81(12):4358-65.
41. Benito M, Vasilic B, Wehrli FW, Bunker B, Wald M, Gomberg B, Wright AC, Zemel B, Cucchiara A, Snyder PJ. Effect of testosterone replacement on trabecular architecture in hypogonadal men. *J Bone Miner Res*. 2005 Oct;20(10):1785-91.
42. Finkelstein JS, Klibanski A, Neer RM, Doppelt SH, Rosenthal DI, Segre GV, Crowley WF Jr. Increases in bone density during treatment of men with idiopathic hypogonadotropic hypogonadism. *J Clin Endocrinol Metab*. 1989 Oct;69(4):776-83.
43. Wang C, Cunningham G, Dobs A, Iranmanesh A, Matsumoto AM, Snyder PJ, Weber T, Berman N, Hull L, Swerdloff RS. Long-term testosterone gel (AndroGel) treatment maintains beneficial effects on sexual function and mood, lean and fat mass, and bone mineral density in hypogonadal men. *J Clin Endocrinol Metab*. 2004 May;89(5):2085-98.
43. Amory JK, Watts NB, Easley KA, Sutton PR, Anawalt BD, Matsumoto AM, Bremner WJ, Tenover JL. Exogenous testosterone or testosterone with finasteride increases bone mineral density in older men with low serum testosterone. *J Clin Endocrinol Metab*. 2004 Feb;89(2):503-10.
44. Snyder PJ, Peachey H, Hannoush P, Berlin JA, Loh L, Holmes JH, Dlewati A, Staley J, Santanna J, Kapoor SC, Attie MF, Haddad JG Jr, Strom BL. Effect of testosterone treatment on bone mineral density in men over 65 years of age. *J Clin Endocrinol Metab*. 1999 Jun;84(6):1966-72.
45. Basurto L, Zarate A, Gomez R, Vargas C, Saucedo R, Galván R. Effect of testosterone therapy on lumbar spine and hip mineral density in elderly men. *Aging Male*. 2008 Sep;11(3):140-5.
46. Snyder PJ, Kopperdahl DL, Stephens-Shields AJ, Ellenberg SS, Cauley JA, Ensrud KE, Lewis CE, Barrett-Connor E, Schwartz AV, Lee DC, Bhasin S, Cunningham GR, Gill TM, Matsumoto AM, Swerdloff RS, Basaria S, Diem SJ, Wang C, Hou X, Cifelli D, Dougar D, Zeldow B, Bauer DC, Keaveny TM. Effect of Testosterone Treatment on Volumetric Bone Density and Strength in Older Men With Low Testosterone: A Controlled Clinical Trial. *JAMA Intern Med*. 2017 Apr 1;177(4):471-479.
47. Watts NB, Adler RA, Bilezikian JP, Drake MT, Eastell R, Orwoll ES, Finkelstein JS; Endocrine Society. Osteoporosis in men: an Endocrine Society clinical practice guideline. *J Clin Endocrinol Metab*. 2012 Jun;97(6):1802-22.
48. LeBoff MS, Greenspan SL, Insogna KL, Lewiecki EM, Saag KG, Singer AJ, Siris ES. The clinician's guide to prevention and treatment of osteoporosis. *Osteoporos Int*. 2022 Oct;33(10):2049-2102.
49. Qaseem A, Forciea MA, McLean RM, Denberg TD; Clinical Guidelines Committee of the American College of Physicians; Barry MJ, Cooke M, Fitterman N, Harris RP, Humphrey LL, Kansagara D, McLean RM, Mir TP, Schünemann HJ. Treatment of Low Bone Density or Osteoporosis to Prevent Fractures in Men and Women: A Clinical Practice Guideline Update From the American College of Physicians. *Ann Intern Med*. 2017 Jun 6;166(11):818-839.
50. Papaioannou A, Morin S, Cheung AM, Atkinson

- S, Brown JP, Feldman S, Hanley DA, Hodsman A, Jamal SA, Kaiser SM, Kvern B, Siminoski K, Leslie WD; Scientific Advisory Council of Osteoporosis Canada. 2010 clinical practice guidelines for the diagnosis and management of osteoporosis in Canada: summary. *CMAJ*. 2010 Nov 23;182(17):1864-73.
51. Orwoll E, Ettinger M, Weiss S, Miller P, Kendler D, Graham J, Adami S, Weber K, Lorenc R, Pieteschmann P, Vandormael K, Lombardi A. Alendronate for the treatment of osteoporosis in men. *N Engl J Med*. 2000 Aug 31;343(9):604-10.
 52. Ringe JD, Faber H, Dorst A. Alendronate treatment of established primary osteoporosis in men: results of a 2-year prospective study. *J Clin Endocrinol Metab*. 2001 Nov;86(11):5252-5.
 53. Ringe JD, Faber H, Farahmand P, Dorst A. Efficacy of risedronate in men with primary and secondary osteoporosis: results of a 1-year study. *Rheumatol Int*. 2006 Mar;26(5):427-31.
 54. Ringe JD, Farahmand P, Faber H, Dorst A. Sustained efficacy of risedronate in men with primary and secondary osteoporosis: results of a 2-year study. *Rheumatol Int*. 2009 Jan;29(3):311-5.
 55. Boonen S, Orwoll ES, Wenderoth D, Stoner KJ, Eusebio R, Delmas PD. Once-weekly risedronate in men with osteoporosis: results of a 2-year, placebo-controlled, double-blind, multicenter study. *J Bone Miner Res*. 2009 Apr;24(4):719-25.
 56. Lyles KW, Colón-Emeric CS, Magaziner JS, Adachi JD, Pieper CF, Mautalen C, Hyldstrup L, Recknor C, Nordsletten L, Moore KA, Lavecchia C, Zhang J, Mesenbrink P, Hodgson PK, Abrams K, Orloff JJ, Horowitz Z, Eriksen EF, Boonen S; HORIZON Recurrent Fracture Trial. Zoledronic acid and clinical fractures and mortality after hip fracture. *N Engl J Med*. 2007 Nov 1;357(18):1799-809.
 57. Boonen S, Reginster JY, Kaufman JM, Lippuner K, Zanchetta J, Langdahl B, Rizzoli R, Lipschitz S, Dimai HP, Witvrouw R, Eriksen E, Brixen K, Russo L, Claessens F, Papanastasiou P, Antunez O, Su G, Bucci-Rechtweg C, Hruska J, Incera E, Vanderschueren D, Orwoll E. Fracture risk and zoledronic acid therapy in men with osteoporosis. *N Engl J Med*. 2012 Nov 1;367(18):1714-23.
 58. Orwoll E, Tegljbærg CS, Langdahl BL, Chapurlat R, Czerwinski E, Kendler DL, Reginster JY, Kivitz A, Lewiecki EM, Miller PD, Bolognese MA, McClung MR, Bone HG, Ljunggren Ö, Abrahamsen B, Gruntmanis U, Yang YC, Wagman RB, Siddhanti S, Grauer A, Hall JW, Boonen S. A randomized, placebo-controlled study of the effects of denosumab for the treatment of men with low bone mineral density. *J Clin Endocrinol Metab*. 2012 Sep;97(9):3161-9.
 59. Orwoll ES, Scheele WH, Paul S, Adami S, Syversen U, Diez-Perez A, Kaufman JM, Clancy AD, Gaich GA. The effect of teriparatide [human parathyroid hormone (1-34)] therapy on bone density in men with osteoporosis. *J Bone Miner Res*. 2003 Jan;18(1):9-17.
 60. Czerwinski E, Cardona J, Plebanski R, Recknor C, Vokes T, Saag KG, Binkley N, Lewiecki EM, Adachi J, Knychas D, Kendler D, Orwoll E, Chen Y, Pearman L, Li YH, Mitlak B. The Efficacy and Safety of Abaloparatide-SC in Men With Osteoporosis: A Randomized Clinical Trial. *J Bone Miner Res*. 2022 Dec;37(12):2435-2442.
 61. Lewiecki EM, Blicharski T, Goemaere S, Lippuner K, Meisner PD, Miller PD, Miyauchi A, Maddox J, Chen L, Horlait S. A Phase III Randomized Placebo-Controlled Trial to Evaluate Efficacy and Safety of Romosozumab in Men With Osteoporosis. *J Clin Endocrinol Metab*. 2018 Sep 1;103(9):3183-3193.